Journal of Medicinal Chemistry p. 652 - 658 (1987)
Update date:2022-08-05
Topics: in vivo Redox Chemistry
Atwell, Graham J.
Rewcastle, Gordon W.
Baguley, Bruce C.
Denny, William A.
Structure-activity relationships for a series of acridine-substituted 3'-N(CH3)2 derivatives of the clinical antileukemic drug amsacrine (1) are reported.The parent (unsubstituted) compound 3 has activity against the Lewis lung solid tumor that is superior to amsacrine(1), the new clinical amsacrine analogue 4, and the recently developed 3'-NHCH3 derivative 2.Although the compounds generally bind less well to DNA and are less dose potent in vivo than either their amsacrine (3'-OCH3) or 3'-NHCH3 analogues, they show very high levels of antitumor activity, with the 4-OCH3 derivative capable of effecting 100percent cures of the Lewis lung solid tumor.The broad structure-activity relationships for acridine substitution more closely resemble those of the amsacrine than the 3'-NHCH3 series, with 4-substituted and 4,5-disubstituted compounds showing the highest activity.
View Morewebsite:http://www.finerchem.com
Contact:+86-531-88989536
Address:New Material Industry Park, Jinan Ciyt, China
Nanjing Chemipioneer Pharma&Tech Co.,Ltd
website:http://www.chemipioneer.com.cn
Contact:+86-25-52685700
Address:Room 305,A Block,Biological-Medicine Building,Business Start-up Center,Xin-ke 1st Road, High-tech development zone,Nanjing city,Jiangsu Province, China
website:http://www.tcfinechem.com/
Contact:18681346930
Address:baifu town,whou district
Jiacheng-Chem Enterprises Limited(expird)
Contact:86-571-86711508
Address:19 Floor, CIBC Holley International Building, No. 198,Wuxing Road, Hangzhou, China,310020
Contact:+8618766299236
Address:ROOM808, BUILDING2,NO.230 SHEN ZHEN ROAD, LAOSHAN DISTRICT
Doi:10.1016/j.tetlet.2016.06.036
(2016)Doi:10.1002/ejoc.202000066
(2020)Doi:10.1016/j.bmc.2006.02.021
(2006)Doi:10.1016/S0040-4039(00)71988-5
(1975)Doi:10.1021/ol034736n
(2003)Doi:10.1021/jo00908a023
(1975)